Skip to main content

42 - References

References

838 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 10 References

  1. Marrie RA, et  al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler 2015; 21:305–317.
  2. Gottberg K, et al. A population-­based study of depressive symptoms in multiple sclerosis in Stockholm county: association with functioning and sense of coherence. J Neurol Neurosurg Psychiatry 2007; 78:60–65.
  3. Boeschoten RE, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-­analysis. J Neurol Sci 2017; 372:331–341.
  4. Patten SB, et al. Depression in multiple sclerosis. Int Rev Psychiatry 2017; 29:463–472.
  5. Kalb R, et al. Depression and suicidality in multiple sclerosis: red flags, management strategies, and ethical considerations. Curr Neurol Neurosci Rep 2019; 19:77.
  6. Sadovnick AD, et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41:1193–1196.
  7. Strupp J, et al. Risk factors for suicidal ideation in patients feeling severely affected by multiple sclerosis. J Palliat Med 2016; 19:523–528.
  8. Sparaco M, et al. Psychiatric disorders in multiple sclerosis. J Neurol 2021; 268:45–60.
  9. Corallo F, et al. A complex relation between depression and multiple sclerosis: a descriptive review. Neurol Sci 2019; 40:1551–1558.
  10. Menculini G, et al. Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction. J Neurol Neurosurg Psychiatry 2023; 94:389–395.
  11. Moran PJ, et al. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005; 28:35–41.
  12. Pandya R, et al. Predictive value of the CES-­D in detecting depression among candidates for disease-­modifying multiple sclerosis treatment. Psychosomatics 2005; 46:131–134.
  13. Minden SL, et al. Evidence-­based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014; 82:174–181.
  14. Rickards H. Depression in neurological disorders: Parkinson’s disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry 2005; 76 Suppl 1:i48–i52.
  15. Silveira C, et al. Neuropsychiatric symptoms of multiple sclerosis: state of the art. Psychiatry Investig 2019; 16:877–888.
  16. Patten SB. Current perspectives on co-­morbid depression and multiple sclerosis. Expert Rev Neurother 2020; 20:867–874.
  17. McIntosh GE, et al. Clinical practice guidelines for the detection and treatment of depression in multiple sclerosis: a systematic review. Neurol Clin Pract 2023; 13:e200154.
  18. Mohr DC, et al. Comparative outcomes for individual cognitive-­behavior therapy, supportive-­expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol 2001; 69:942–949.
  19. Ehde DM, et al. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry 2008; 30:40–48.
  20. Flax JW, et al. Effect of fluoxetine on patients with multiple sclerosis. Am J Psychiatry 1991; 148:1603.
  21. Vollmer TL, et al. A randomized, double-­blind, placebo-­controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis. Pain Pract 2014; 14:732–744.
  22. Hilty DM, et al. Psychopharmacology for neurologists: principles, algorithms, and other resources. Continuum 2006; 12:33–46.
  23. Barak Y, et al. Treatment of depression in patients with multiple sclerosis. Neurologist 1998; 4:99–104.
  24. Koch MW, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev 2011; 2:CD007295.
  25. Taylor D, et al. Pharmacological interventions for people with depression and chronic physical health problems: systematic review and meta-­ analyses of safety and efficacy. Br J Psychiatry 2011; 198:179–188.
  26. Baghbanian SM, et al. The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: a double-­blind randomized clinical trial. Mult Scler Relat Disord 2023; 69:104399.
  27. Gil-­Sanchez A, et al. Effects of vortioxetine on cognition and fatigue in patients with multiple sclerosis and depression: a case series study. CNS Neurol Disord Drug Targets 2024; 23:395–401.
  28. Siegert RJ, et al. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005; 76:469–475.
  29. Larcombe NA, et al. An evaluation of cognitive-­behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatry 1984; 145:366–371.
  30. Grossman P, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010; 75:1141–1149.
  31. Shinto L, et al. Omega-­3 fatty acids for depression in multiple sclerosis: a randomized pilot study. PLoS One 2016; 11:e0147195.
  32. Schiffer RB, et  al. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry 1990; 147:1493–1497.
  33. Barak Y, et al. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-­label safety trial. J Neuropsychiatry Clin Neurosci 1999; 11:271–273.
  34. Shkodina AD, et al. Pharmacological and non-­pharmacological approaches for the management of neuropathic pain in multiple sclerosis. CNS Drugs 2024; 38:205–224.
  35. Rasmussen KG, et al. Electroconvulsive therapy in patients with multiple sclerosis. J ECT 2007; 23:179–180.
  36. Jones KH, et al. A large-­scale study of anxiety and depression in people with multiple sclerosis: a survey via the web portal of the UK MS Register. PLoS One 2012; 7:e41910.
  37. Korostil M, et al. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007; 13:67–72.
  38. Butler E, et al. ‘It’s the unknown’ – understanding anxiety: from the perspective of people with multiple sclerosis. Psychol Health 2019; 34:368–383.

Drug treatment of psychiatric symptoms in the context of other conditions CHAPTER 10 39. Solaro C, et al. Pregabalin for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study. J Neurol 2009; 256:1773–1774. 40. Bittner S, et  al. [Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications]. Nervenarzt 2011; 82:1273–1280. 41. Nabizadeh F, et  al. Pseudobulbar affect in neurodegenerative diseases: a systematic review and meta-­analysis. J Clin Neurosci 2022; 100:100–107. 42. Feinstein A, et al. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 1999; 5:323–326. 43. Feinstein A, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 1997; 54:1116–1121. 44. Andersen G, et al. Citalopram for post-­stroke pathological crying. Lancet 1993; 342:837–839. 45. Robinson RG, et al. Pathological laughing and crying following stroke: validation of a measurement scale and a double-­blind treatment study. Am J Psychiatry 1993; 150:286–293. 46. Burns A, et al. Sertraline in stroke-­associated lability of mood. Int J Geriatr Psychiatry 1999; 14:681–685. 47. Johnson B, et al. Crying and suicidal, but not depressed. Pseudobulbar affect in multiple sclerosis successfully treated with valproic acid: case report and literature review. Palliat Support Care 2015; 13:1797–1801. 48. Pioro EP, et al. Dextromethorphan plus ultra low-­dose quinidine reduces pseudobulbar affect. Ann Neurol 2010; 68:693–702. 49. McGrane I, et  al. Treatment of pseudobulbar affect with fluoxetine and dextromethorphan in a woman with multiple sclerosis. Ann Pharmacother 2017; 51:1035–1036. 50. Joseph B, et al. Prevalence of bipolar disorder in multiple sclerosis: a systematic review and meta-­analysis. Evid Based Ment Health 2021; 24:88–94. 51. Patten SB, et al. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler 2000; 6:115–120. 52. Davids E, et al. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:743–744. 53. Budur K, et al. Olanzapine for corticosteroid-­induced mood disorders. Psychosomatics 2003; 44:353. 54. Camara-­Lemarroy CR, et al. The varieties of psychosis in multiple sclerosis: a systematic review of cases. Mult Scler Relat Disord 2017; 12:9–14. 55. Jefferies K. The neuropsychiatry of multiple sclerosis. Adv Psychiatric Treat 2006; 12:214–220. 56. Narita Z, et al. Possible effects of electroconvulsive therapy on refractory psychosis in primary progressive multiple sclerosis: a case report. Neuropsychopharmacol Rep 2018; 38:92–94. 57. Stamoula Ε, et al. Atypical antipsychotics in multiple sclerosis: a review of their in vivo immunomodulatory effects. Mult Scler Relat Disord 2022; 58:103522. 58. Aragona M, et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-­blind, placebo controlled, crossover study. Clin Neuropharmacol 2009; 32:41–47. 59. Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-­analysis. Lancet Psychiatry 2019; 6:995–1010. 60. Pierson SH, et al. Treatment of cognitive impairment in multiple sclerosis. Behav Neurol 2006; 17:53–67. 61. Krupp LB, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004; 63:1579–1585. 62. Greene YM, et al. A 12-­week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. J Clin Psychopharmacol 2000; 20:350–356. 63. Krupp LB, et  al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011; 76:1500–1507. 64. Lovera JF, et  al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-­controlled trial. Mult Scler 2010; 16:715–723. 65. Chen MH, et al. Cognitive efficacy of pharmacologic treatments in multiple sclerosis: a systematic review. CNS Drugs 2020; 34:599–628. 66. Patti F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs 2012; 21:1679–1699. 67. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003; 9:219–227. 68. Sepulcre J, et  al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009; 15:337–344. 69. Ormstad H, et al. Chronic fatigue and depression due to multiple sclerosis: immune-­inflammatory pathways, tryptophan catabolites and the gut-­brain axis as possible shared pathways. Mult Scler Relat Disord 2020; 46:102533. 70. Van KK, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med 2008; 70:205–213. 71. Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007; 1:CD002818. 72. National Institute for Health and Care Excellence. Multiple sclerosis in adults: management. NICE guideline [NG220]. 2022 (last checked May 2024); https://www.nice.org.uk/guidance/ng220. 73. Yang TT, et al. Pharmacological treatments for fatigue in patients with multiple sclerosis: a systematic review and meta-­analysis. J Neurol Sci 2017; 380:256–261. 74. Perez DQ, et al. Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-­analysis. Neurodegener Dis Manag 2020; 10:383–395. 75. Shangyan H, et al. Meta-­analysis of the efficacy of modafinil versus placebo in the treatment of multiple sclerosis fatigue. Mult Scler Relat Disord 2018; 19:85–89. 76. Davies M, et al. Safety profile of modafinil across a range of prescribing indications, including off-­label use, in a primary care setting in England: results of a modified prescription-­event monitoring study. Drug Saf 2013; 36:237–246. 77. López-­Muñoz P, et al. Effect of vitamin D supplementation on fatigue in multiple sclerosis: a systematic review and meta-­analysis. Nutrients 2023; 15:2861.

No comments to display

Back to top